Form 4 for BIIB Biogen
Accepted 2025-02-10 00:00:00 ET · period of report 2025-02-06 · accession 0001127602-25-003961 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-02-10 | 2025-02-07 | BIIB | Grogan Jane | Head of Research | F - Tax | $141.35 | -443 | 1,433 | -24% | -$62.6K |
| D | 2025-02-10 | 2025-02-07 | BIIB | Grogan Jane | Head of Research | M - OptEx | $0.00 | +1,385 | 1,876 | +282% | $0 |
| D | 2025-02-10 | 2025-02-07 | BIIB | Grogan Jane | Head of Research | M - OptEx | $0.00 | -1,385 | 2,770 | -33% | $0 |
| D | 2025-02-10 | 2025-02-06 | BIIB | Grogan Jane | Head of Research | A - Grant | $0.00 | +5,620 | 5,620 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-07 | F | D | 443 | $141.35 | 1,433 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-07 | M | A | 1,385 | $0.00 | 1,876 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2025-02-07 | M | D | 1,385 | $0.00 | 2,770 | D | $0.00 · — to 2027-02-07 | 1,385 Common Stock | (F2) The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. |
| 4 | Derivative | Restricted Stock Unit | 2025-02-06 | A | A | 5,620 | $0.00 | 5,620 | D | $0.00 · — to 2028-02-06 | 5,620 Common Stock | (F1) The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025. |